Every 8-K that Aclaris Therapeutics, Inc. (ACRS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ACRS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACRS filings page.
Aclaris Therapeutics, Inc. entered into a Second Amended and Restated Sales Agreement on August 6, 2026 with Leerink Partners LLC and Cantor Fitzgerald & Co., allowing it to offer and sell shares of common stock from time to time through these firms as sales agents under a Form S-3 shelf.
Sales may be conducted as an “at the market offering” under Rule 415, with Leerink and Cantor using commercially reasonable efforts subject to Aclaris’ instructions. Aclaris will pay a 3.0% commission on gross proceeds, is not obligated to sell any shares, and the prior 2025 agreement allowed sales of up to $100.0 million of common stock.
Aclaris Therapeutics, Inc. reported financial results for the quarter and six months ended June 30, 2026 and provided a corporate and clinical update. For the second quarter, total revenue was $1.6 million and net loss was $21.5 million. For the first half of 2026, net loss was $41.3 million, with research and development expenses of $33.7 million driven mainly by ATI-052 and ATI-9494 development, and general and administrative expenses of $12.8 million.
As of June 30, 2026, Aclaris held $170.6 million in cash, cash equivalents and marketable securities and stated that this is expected to fund operations through the end of 2028. After quarter-end, it sold 7.3 million shares via its at-the-market program for $40.2 million in gross proceeds to support planned Phase 2b and proof-of-concept trials. The update highlighted upcoming placebo-controlled top line data from Phase 1b POC trials of ATI-052 in asthma and atopic dermatitis, a Phase 2 trial of bosakitug in atopic dermatitis, planned Phase 2b programs for ATI-052 and modzatinib, and an expected IND filing for ATI-9494.
Aclaris Therapeutics, Inc. held its 2026 annual meeting of stockholders on June 4, 2026. Stockholders representing 112,499,671 shares, or approximately 80.55% of the 139,663,680 shares outstanding as of the record date, were present or represented by proxy, providing a strong quorum.
Two directors, Anand Mehra, M.D. and Maxine Gowen, Ph.D., were elected to serve until the 2029 annual meeting. An advisory vote approved the compensation of the company’s named executive officers. Stockholders also ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Aclaris Therapeutics reported a larger net loss in the first quarter of 2026 as it increased investment in its immuno-inflammatory pipeline, while strengthening its cash position. Net loss was $19.8 million for the quarter, compared with $15.1 million a year earlier.
Total revenue was $2.0 million, up from $1.5 million, mainly from higher royalties under the Lilly and Sun Pharma license agreements. Research and development expenses rose to $15.7 million, driven by clinical work on ATI-052 and manufacturing costs for ATI-9494, partly offset by lower spending on ATI-2138.
In March 2026, Aclaris sold 18.4 million shares of common stock for gross proceeds of $59.8 million. Cash, cash equivalents and marketable securities were $190.8 million as of March 31, 2026, and the company believes this will fund operations through the end of 2028 while it advances programs including ATI-052, ATI-2138, bosakitug and ATI-9494.
Aclaris Therapeutics announced positive full top line results from a first‑in‑human Phase 1a trial of ATI‑052, a bispecific antibody targeting TSLP and IL‑4Rα. The study in healthy volunteers tested single doses up to 720 mg and multiple weekly doses up to 480 mg and showed a favorable safety, pharmacokinetic, and pharmacodynamic profile with an estimated half‑life of about 45 days, supporting the potential for dosing as infrequently as every three months.
The company is enrolling Phase 1b proof‑of‑concept trials of ATI‑052 in asthma and atopic dermatitis, with top line data planned for the second half of 2026 and a Phase 2b asthma program expected to start in the fourth quarter of 2026. Aclaris also selected lichen planus (LP) as the lead indication for its oral ITK/JAK3 inhibitor ATI‑2138 and plans a multi‑part Phase 2b basket trial in LP subtypes beginning in the second half of 2026, citing a potential U.S. market opportunity above $1.0 billion and up to $4.0 billion.
Aclaris Therapeutics reported that on March 10, 2026 it sold 5.7 million shares of its common stock, generating $20.0 million in aggregate gross proceeds. The sale was made under its amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co.
The agents informed the company that the shares were purchased by Frazier Life Sciences, Kalehua Capital and Adage Capital Partners LP. The disclosure is furnished under Regulation FD and is not treated as filed for liability purposes under the Exchange Act.
Aclaris Therapeutics, Inc. reported that from March 2–9, 2026 it sold 12.7 million shares of its common stock through its amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co.
These sales generated aggregate gross proceeds of $39.8 million and the shares were purchased by institutional investors, including Deep Track Capital. The disclosure is provided under Regulation FD and is expressly not deemed filed for liability purposes under Section 18 of the Exchange Act.
Aclaris Therapeutics reported fourth quarter and full-year 2025 results and highlighted progress across its immuno-inflammatory pipeline. Net loss narrowed to $19.8 million in Q4 2025 from $96.6 million a year earlier, and to $64.9 million for 2025 from $132.1 million in 2024.
Total revenue was $1.3 million in Q4 2025 and $7.8 million for the year, reflecting lower licensing revenue after a 2024 milestone. R&D expenses rose to $52.6 million in 2025 as the company advanced bosakitug, ATI-052 and ATI-9494.
Cash, cash equivalents and marketable securities were $151.4 million as of December 31, 2025. Aclaris expects this to fund operations into the second half of 2028. The company reported positive interim Phase 1a data for ATI-052, initiated Phase 1b trials in atopic dermatitis and asthma, and plans a Phase 2 bosakitug readout and an IND filing for ATI-9494 in 2026.
Aclaris Therapeutics, Inc. furnished an updated corporate overview presentation as part of a current report under Regulation FD. The presentation is attached as Exhibit 99.1 and is also available on the company’s website, providing an overview of its business for investors and other stakeholders. The company states that this material is being furnished, not filed, so it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other securities law filings unless specifically referenced.
Aclaris Therapeutics, Inc. furnished an 8-K to share its latest financial update. The company issued a press release announcing financial results for the quarter and nine-month period ended September 30, 2025. This update is provided to keep investors informed about recent operating performance and financial condition.
The press release is attached as Exhibit 99.1 and is furnished rather than filed, which means it is not automatically incorporated into other SEC reports unless specifically referenced. The 8-K is signed on behalf of the company by Chief Financial Officer Kevin Balthaser.
Aclaris Therapeutics will host an in-person and virtual R&D Day on October 14, 2025 at 8:00 a.m. ET, with a live webcast available on the Investors Events page. The accompanying company presentation is furnished as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure). The information in Item 7.01 and Exhibit 99.1 is not deemed “filed” under the Exchange Act or Securities Act, except if expressly incorporated by reference.
On 30 June 2025, Aclaris Therapeutics, Inc. (Nasdaq: ACRS) filed an 8-K solely to furnish an updated corporate overview presentation (Exhibit 99.1) under Item 7.01 – Regulation FD Disclosure. The deck has been posted to the company’s website and is not deemed “filed” for Exchange Act liability or for incorporation by reference. No financial results, strategic transactions, or operational updates were disclosed. All other sections, including Item 9.01, merely list the exhibit numbers, and the filing was signed by CFO Kevin Balthaser.